| Literature DB >> 30186541 |
Mayra Alejandra Mendez-Encinas1, Elizabeth Carvajal-Millan1, Agustín Rascon-Chu2, Humberto Francisco Astiazaran-Garcia3, Dora Edith Valencia-Rivera4.
Abstract
In the last years, biomedical research has focused its efforts in the development of new oral delivery systems for the treatment of different diseases. Ferulated arabinoxylans are polysaccharides from cereals that have been gaining attention in the pharmaceutical field due to their prebiotic, antioxidant, and anticancer properties. The antioxidant and anticancer properties of these polysaccharides make them attractive compounds for the treatment of cancer, particularly colon cancer. In addition, ferulated arabinoxylans can form covalent gels through the cross-linking of their ferulic acids. Due to their particular characteristics, ferulated arabinoxylan gels represent an excellent alternative as colon-targeted drug delivery systems. The aim of the present work is to review the physicochemical and functional properties of ferulated arabinoxylans and their gels and to present the future perspectives for potential application as antioxidant and anticancer agents.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30186541 PMCID: PMC6116397 DOI: 10.1155/2018/2314759
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1(a) Chemical structure of AX and (b) arabinose substitution in AX chain.
Origin, FA content, and current/potential application of AX in biomedical and pharmaceutical fields.
| AX origin | FA content ( | Currently/potential application in biomedical/pharmaceutical field | Reference |
|---|---|---|---|
| Nejayote/maize bran | 0.012/0.025 | Entrapment of probiotic | [ |
| Nejayote/maize bran | 0.012/0.025 | Entrapment and controlled release of insulin and probiotics targeted to colon | [ |
| Maize bran | 0.34 | Controlled release of insulin and | [ |
| Maize bran | 0.25 | Controlled release of insulin targeted to colon | [ |
| Maize bran | 4.0 | Entrapment and controlled release of methyl xanthine | [ |
| Wheat endosperm | 2.3 | Controlled release of proteins | [ |
| Wheat endosperm | 0.53 | Entrapment of probiotics | [ |
| Wheat bran | 0.435 | Antitumor and immunomodulatory activity | [ |
| Wheat bran | — | Prebiotic | [ |
| Rice bran | — | Antitumor and immunomodulatory activity | [ |
| Rice bran (MGN-3/Biobran) | — | Cancer immunotherapy | [ |
| Finger millet bran | 0.001 | Immunomodulatory activity | [ |
| Ispaghula ( | nd | Drug carrier | [ |
| Ispaghula ( | — | Controlled release of mucoadhesive oral films | [ |
nd: no detectable; −: no reported.
Figure 2(a) Schematic representation of FA dimerization. (b) Covalent cross-linking of ferulated AX. Formation of 8-5′ di-FA is presented as an example. AX: arabinoxylan; FA: ferulic acid; di-FA: ferulic acid dimer.
In vivo studies on the evaluation of the prebiotic effect of AX.
| Animal model | Diet/experimental time | Findings | Reference |
|---|---|---|---|
| Male chickens | Control diet (CT), diet supplemented with XOS, wheat bran-derived AXOS, wheat endosperm alkali-solubilized AX. 2 w | All treatments increased bifidobacteria. AX decreased body weight gain after 2 weeks of feeding compared with CT. | [ |
|
| |||
| Male C57bl6/J mice | Control diet, high-fat (HF) diet, HF diet supplemented with AX. 4 w | HF diet supplemented with AX restored microbiota with a major effect on | [ |
|
| |||
| Male germ-free Fisher 344 albino rats inoculated with human faecal microbiota | Control diet, diet supplemented with long-chain AX (LC-AX) and diet supplemented with inulin (IN). 6 w | LC-AX and IN increased SCFA levels (propionate and butyrate, resp.). Stimulation of butyrate-producing bacteria and bifidobacteria, respectively. Reduction of mucin-degrading | [ |
|
| |||
| Male Wistar rats | Diets supplemented with WU-AX, WE-AX, and AXOS. 14 days | WU-AX supplementation increased butyrate production and butyrate-producing bacteria. WE-AX and/or AXOS reduced pH, suppressed relevant markers of proteolytic breakdown, and induced selective bifidogenic response. Combination of WU-AX, WE-AX, and AXOS showed a synergic effect. | [ |
|
| |||
| Male C57bl6/J mice | Control diet, high-fat (HF) diet, HF diet supplemented with AXOS. 8 w | AXOS supplementation exerted a bifidogenic effect. Improvement of the HF-induced body weight gain, fat mass development, hyperinsulinemia, insulin resistance, endotoxemia, and inflammatory disorders in a model of HF diet-induced obesity. | [ |
|
| |||
| Pigs | Low dietary fiber and high-fat diet (WSD), AX-rich diet (AXD), and resistant starch diet (RS). 3 w | AXD feeding shifted the microbial composition towards butyrogenic species in the faeces and increased the large-intestinal butyrate pool size. | [ |
w: week.
Description of studies evaluating the anticancer potential of AX and AXOS, in vivo.
| Type of cancer/animal model | Carcinogenic agent/cancer cells | Dosage/experimental time | Findings | Reference |
|---|---|---|---|---|
| Solid Erlich carcinoma | Erlich ascites, carcinoma cells, and intramuscular inoculation | MGN-3/Biobran (25 mg/kg bw) ip | MGN-3 suppressed the growth of tumors, normalized lipid peroxidation, and increased glutathione contents. Increased activity of endogenous antioxidant scavenging enzymes (superoxide dismutase, glutathione peroxidase, catalase, and glutathione-S-transferase) in blood, liver, and tumor tissue. | [ |
|
| ||||
| Colon carcinogenesis | 1,2,-Dimethylhydrazine (DMH), subcutaneous injection. | High-fat diet plus AXOS (48 g/kg). | Lower counts of preneoplastic lesions (mucin depleted foci (MDF)) in comparison to the control group. Fewer preneoplastic lesions (aberrant crypt foci (ACF)) in the distal part of the colon. | [ |
|
| ||||
| S180 tumor-bearing mice | Mouse sarcoma S180 cells, intramuscular inoculation. | AX orally administered (100, 200, and 400 mg/kg bw). | Administration of AX significantly inhibited the growth of mouse transplantable tumors and promoted thymus and spleen indexes, splenocyte proliferation, NK cell and macrophage phagocytosis activity, and IL-2 production. Increased peripheral leukocyte count and bone marrow cellularity. | [ |
|
| ||||
| Neuroblastoma | Injection of NB1691luc cells. | NK cells activated with 100 | Significant inhibition of neuroblastoma growth and improvement in survival in the group treated with Biobran. | [ |
|
| ||||
| Glandular stomach carcinogenesis. | Methylnitrosoguanidine (MNNG), via oral gavage. | MNNG plus Biobran (40 mg/kg bw) every other day via oral gavage. | Biobran reduced incidence of animals bearing gastric dysplasia and adenocarcinoma. | [ |
|
| ||||
| Hepatocarcinogenesis. | N-nitrosodiethylamine (NDEA) and carbon tetrachloride (CCl4). | MGN-3/Biobran (25 mg/kg bw), 5 times/week ip | Reduction in liver tumor incidence, decrease of preneoplastic foci in hepatic parenchyma, and inhibition of development of hepatocellular carcinoma. Regulation of AST, ALT, ALP, and gamma GT levels. Increase in cell cycle sub-G0/G1 population. Downregulation of expression of NF- | [ |
bw: body weight; ip: intraperitoneal; AST: serum aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; gamma GT: gamma glutamyl transpeptidase.
Figure 3MGN-3/Biobran enhances the cytotoxicity reactivity of immune cells with anticancer effect and the production of certain cytokines (adapted from [41]).
Figure 4Structural parameters of ferulated AX gels.
Structural parameters of AX gels at 2% (w/v).
| Origin of AX |
|
|
|
|---|---|---|---|
| Wheat (2 | 119 | 201 | 14 |
| Maize (6 | 34 | 96 | 67 |
a[85]. b[25].
Figure 5SEM image of the microstructure of lyophilized AX gel from maize at 1000x.
Figure 6(a) Kinetic of gelation of AX solution (2% w/v) at 0.25 Hz and 5% strain (G′■, G″●, tan δ X) and (b) mechanical spectrum of the AX gel formed, registered at 5% strain (G′■, G″●).
Potential application of AX gels in controlled release of biomolecules and cells.
| AX source | Biomolecule/cell | Potential controlled-release system | Reference |
|---|---|---|---|
| Wheat | Ovalbumin (Ov) | Ov-AX gels for entrapment and controlled release of proteins. 70–88% protein release as Ov/AX ratio increased (24 h | [ |
| Maize bran | Insulin and | AX gels for controlled release of proteins. 11–18% of protein release at the end of a 15 h | [ |
| Maize bran | Lycopene | Lycopene/AX gels for controlled delivery of biomolecules. 3–4% lycopene release at the end of a 4 h | [ |
| Maize bran | Methyl xanthine (caffeine) | AX microparticles. 10% of caffeine release at a 3 h | [ |
| Ispaghula ( | Metronidazole hydrochloride (MH) | MH-loaded calcium gelled AX microspheres for extended drug delivery. 90% MH release at a 70–80 min | [ |
| Maize bran | Insulin | AX microspheres as insulin carriers for colon-specific drug delivery. Insulin release in the colonic region of diabetic rats. | [ |
| Maize waste water (nejayote) and maize bran | Insulin, | Core-shell AX particle (AX-insulin/AX- | [ |
Figure 7Sites of action of enzymes involved in AX degradation.